This move is said to be part of Nanosyn’s strategy to become a worldwide leader in drug discovery services and reflects the company’s evolution from a small regional operation to a larger business on a global scale.
The acquired assets include an industrialized system encompassing high precision microfluidic-based assays, hardware, screening protocols, etc. This new site is currently fully operational and has retained the staff of former Amphora Discovery for screening operations.
Nanosyn has also announced that the intellectual property of former Amphora Discovery including all patents, early leads and advanced lead programs are available for licensing, sale or joint development to interested parties.
Nikolai Sepetov, president and CEO of Nanosyn, said: “It is a natural expansion for us. After 10 years of growth as a pure chemistry contract research organization, we are adding biology services to our clients as many of them are looking for more integrated solutions. Since we can provide both new chemistry and biology in house, we can significantly speed up the drug discovery process for our clients.”